Treatment Information

Back

Melanoma treatment details. Chemotherapy, Immunotherapy.

Campus Benjamin Franklin, Berlin, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:4City/State/Province:Berlin
Treatments:Chemotherapy, ImmunotherapyHospital:Campus Benjamin Franklin
Drugs:Journal:Link
Date:Sep 2005

Description:

Patients: This Phase III study involved a total of 363 patients with metastatic melanoma who were divided into two groups: Group A of 180 patients and Group B of 183 patients. For Group A the median age was 50.

Treatment: The treatment for Group A consisted of two chemotherapy agents (Dacarbazine and Cisplatin) and immunotherapy (interferon-alpha-2b).

Toxicity: Grade 4 toxicities for this group included: vomiting, neuropathy, and shortness of breath. Grade 3 toxicities included cardiovascular dysfunction, hyper or hypotension, various gastrointestinal toxicities, pulmonary, fever, arthralgia, myalgia, and hematologic.

Results: The median overall survival was 9 months.

Support: Several of the authors had received consulting, honorarian or research funding from Schering Plough. This company markets interferon-alpha-2b.

Correspondence: Ulrich Keilholz, MD



Back